Charles River Laboratories (CRL) stock: key figures, P/E, revenue and dividend
Health Care · Life Sciences Tools & Services · United States · ISIN US1598641074
Charles River Laboratories financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 4.02 bn USD |
| Operating income | 25.16 m USD |
| EBIT | 2.59 m USD |
| Net income | -144.34 m USD |
| Diluted EPS – continuing operations | -2.91 USD |
Full history since 1998, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Charles River Laboratories
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has strategic collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization; and Medigen Vaccine Biologics Corp for developing next-generation multivalent enterovirus vaccine, enhance global regulatory readiness, and support IND-enabling non-clinical studies. Additionally, it has a strategic alliance with Francis Crick Institute (Crick), Inc. for the development of Antibody-Drug Conjugate (ADC) drug discovery and development. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
More stocks
- W. P. Carey Inc. (WPC)
- Unum Group (UNM)
- FinecoBank Banca Fineco SpA (FBK.MI)
- Chow Tai Fook Jewellery Group Ltd (1929.HK)
- Equitable Holdings, Inc. (EQH)
- Unibail-Rodamco-Westfield SE (URW.PA)
- Everest Group (EG)
- Huazhu Group Ltd (HTHT)
- SUZHOU CENTEC COMMUNICATIONS LTD A (688702.SS)
- Press Metal Bhd (8869.KL)
- Tyler Technologies (TYL)
- Shanghai Electric Group Co Ltd (601727.SS)
Not investment advice. All data without warranty, price as of 14.10.2026. Details in the risk notice.